Coordinated Trade Group Effort On Dietary Supplement Issues Urged By Hutt
This article was originally published in The Tan Sheet
Executive Summary
The growing number of trade associations with a hand in the dietary supplement industry is a "very troubling" development that requires a coordinated effort to avoid conflicting positions on key regulatory issues, Covington & Burling attorney Peter Barton Hutt commented at the Nutracon '99 conference in Las Vegas July 12-14.
You may also be interested in...
Supplement GMPs
CFSAN to sponsor two regional public meetings on small business economic impact of proposals to establish dietary supplement good manufacturing practices. The first will be held in Salt Lake City Sept. 28 and the second, timed in conjunction with Natural Products Expo East, in Baltimore, Md. Oct. 21, a Sept. 3 Federal Register notice says. Written comments are due Nov. 21. CFSAN held a similar meeting in Las Vegas July 12 (1"The Tan Sheet" July 19, p. 13)
FDA Structure/Function Claim Proposal Meeting Slated For Aug. 4
The definition of "disease" as it pertains to dietary supplement claims will be re-examined at a public meeting in Washington, D.C. Aug. 4, FDA announced in the July 8 Federal Register. The meeting will address three of the more contentious issues raised in comments on the agency's April 29, 1998 proposed rule on structure/function claims (1"The Tan Sheet" May 4, 1998, pp. 1-5).
Henney pledges FDA cooperation with OAM/ODS on alternative medicine therapies.
DSHEA PROVIDES "TOOL" FOR FDA ACTION AGAINST DANGEROUS SUPPLEMENTS, FDA Commissioner-nominee Jane Henney, MD, told the Senate Labor & Human Resources Committee at her confirmation hearing Sept. 2. In response to a question from Sen. Tom Harkin (D-Iowa) on the adequacy of public health protection provided by the Dietary Supplement Health & Education Act, Henney said: "I think Congress in its deliberations tried to strike the right balance in terms of the law that was finally enacted to make dietary supplements available" but also to "give a tool for the FDA to take action when necessary."